Eliot Finkel Investment Counsel LLC boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.3% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 44,470 shares of the biopharmaceutical company’s stock after buying an additional 1,000 shares during the quarter. Gilead Sciences makes up 2.3% of Eliot Finkel Investment Counsel LLC’s holdings, making the stock its 25th biggest position. Eliot Finkel Investment Counsel LLC’s holdings in Gilead Sciences were worth $3,020,000 at the end of the most recent quarter.
Other hedge funds have also recently added to or reduced their stakes in the company. Harel Insurance Investments & Financial Services Ltd. grew its position in shares of Gilead Sciences by 583.3% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $110,000 after purchasing an additional 1,400 shares during the period. Dubuque Bank & Trust Co. grew its position in shares of Gilead Sciences by 19.4% in the first quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock valued at $112,000 after purchasing an additional 267 shares during the period. Penserra Capital Management LLC grew its position in shares of Gilead Sciences by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock valued at $112,000 after purchasing an additional 144 shares during the period. Webster Bank N. A. grew its position in shares of Gilead Sciences by 51.7% in the first quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock valued at $125,000 after purchasing an additional 624 shares during the period. Finally, Cohen Capital Management Inc. acquired a new stake in shares of Gilead Sciences in the first quarter valued at about $157,000. Institutional investors own 74.05% of the company’s stock.
Shares of Gilead Sciences, Inc. (NASDAQ:GILD) traded up 0.09% on Friday, hitting $82.36. 12,296,197 shares of the stock traded hands. The firm has a market cap of $107.56 billion, a P/E ratio of 8.95 and a beta of 1.19. Gilead Sciences, Inc. has a 12-month low of $63.76 and a 12-month high of $86.27. The firm’s 50-day moving average is $76.95 and its 200 day moving average is $70.12.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, topping the consensus estimate of $2.11 by $0.45. The company had revenue of $7.14 billion for the quarter, compared to analysts’ expectations of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The business’s revenue for the quarter was down 8.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.08 earnings per share. Equities research analysts forecast that Gilead Sciences, Inc. will post $8.75 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 28th. Stockholders of record on Friday, September 15th will be issued a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a dividend yield of 2.53%. The ex-dividend date is Thursday, September 14th. Gilead Sciences’s payout ratio is presently 22.58%.
WARNING: This report was first posted by BBNS and is owned by of BBNS. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://baseballnewssource.com/markets/gilead-sciences-inc-gild-shares-bought-by-eliot-finkel-investment-counsel-llc/1605407.html.
Several brokerages have recently issued reports on GILD. Royal Bank Of Canada began coverage on shares of Gilead Sciences in a research report on Thursday. They issued an “outperform” rating and a $94.00 target price on the stock. ValuEngine lowered shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research report on Wednesday. TheStreet upgraded shares of Gilead Sciences from a “c+” rating to a “b-” rating in a research report on Thursday, September 7th. Zacks Investment Research lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Monday. Finally, Berenberg Bank reiterated a “buy” rating and issued a $96.00 target price (up previously from $86.00) on shares of Gilead Sciences in a research report on Wednesday, September 6th. Eleven research analysts have rated the stock with a hold rating and twenty have assigned a buy rating to the stock. Gilead Sciences presently has an average rating of “Buy” and an average price target of $83.79.
In related news, EVP Gregg H. Alton sold 5,000 shares of the firm’s stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $71.06, for a total value of $355,300.00. Following the transaction, the executive vice president now owns 102,988 shares in the company, valued at $7,318,327.28. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider John C. Martin sold 73,333 shares of the firm’s stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $71.00, for a total value of $5,206,643.00. Following the completion of the transaction, the insider now owns 3,199,969 shares in the company, valued at approximately $227,197,799. The disclosure for this sale can be found here. Insiders have sold 466,819 shares of company stock worth $36,740,240 in the last 90 days. Company insiders own 1.30% of the company’s stock.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with our FREE daily email newsletter.